Explore

Trendline Trendline
Ribo Submits Phase 2 Trial for siRNA Therapeutic to EMA

Ribo Submits Phase 2 Trial for siRNA Therapeutic to EMA

Ribo Submits Phase 2 Trial for siRNA Therapeutic to EMA
Trendline Trendline
GSK's Bepirovirsen Shows Promising Cure Rates for Chronic Hepatitis B

GSK's Bepirovirsen Shows Promising Cure Rates for Chronic Hepatitis B

GSK's Bepirovirsen Shows Promising Cure Rates for Chronic Hepatitis B
Trendline Trendline
Biopharma Companies Explore PD-(L)1×VEGF Bispecifics Beyond Lung Cancer

Biopharma Companies Explore PD-(L)1×VEGF Bispecifics Beyond Lung Cancer

Biopharma Companies Explore PD-(L)1×VEGF Bispecifics Beyond Lung Cancer
AP News AP News
Experimental hepatitis B drug may offer 'functional cure' for some patients

Experimental hepatitis B drug may offer 'functional cure' for some patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
Trendline Trendline
Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy

Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy

Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy
Trendline Trendline
Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer

Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer

Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer
Trendline Trendline
Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments

Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments

Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments
Trendline Trendline
Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
AP News AP News
Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus
Trendline Trendline
Retension Pharmaceuticals Appoints New Executives to Advance Hypertension Treatment

Retension Pharmaceuticals Appoints New Executives to Advance Hypertension Treatment

Retension Pharmaceuticals Appoints New Executives to Advance Hypertension Treatment
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity